Hiroshi Soeda

Sendai, Japan

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 8 publications

CpG island methylator phenotype is associated with the efficacy of sequential oxaliplatin- and irinotecan-based chemotherapy and EGFR-related gene mutation in Japanese patients with metastatic colorectal cancer.

CpG island methylator phenotype is associated with the efficacy of sequential oxaliplatin- and irinotecan-based chemotherapy and EGFR-related gene mutation in Japanese patients with metastatic colorectal cancer.

Journal: International journal of clinical oncology

Published: February 12, 2016

Gene-expression profiles correlate with the efficacy of anti-EGFR therapy and chemotherapy for colorectal cancer.

Gene-expression profiles correlate with the efficacy of anti-EGFR therapy and chemotherapy for colorectal cancer.

Journal: International journal of clinical oncology

Published: February 25, 2015

Functional Complementation Assay for 47 MUTYH Variants in a MutY-Disrupted Escherichia coli Strain.

Functional Complementation Assay for 47 MUTYH Variants in a MutY-Disrupted Escherichia coli Strain.

Journal: Human mutation

Published: May 27, 2014

Preliminary estimation of the prevalence of chemotherapy-induced dysgeusia in Japanese patients with cancer.

Preliminary estimation of the prevalence of chemotherapy-induced dysgeusia in Japanese patients with cancer.

Journal: BMC palliative care

Published: May 26, 2013

Phase II trial of cetuximab plus irinotecan for oxaliplatin- and irinotecan-based chemotherapy-refractory patients with advanced and/or metastatic colorectal cancer: evaluation of efficacy and safety based on KRAS mutation status (T-CORE0801).

Phase II trial of cetuximab plus irinotecan for oxaliplatin- and irinotecan-based chemotherapy-refractory patients with advanced and/or metastatic colorectal cancer: evaluation of efficacy and safety based on KRAS mutation status (T-CORE0801).

Journal: Oncology

Published: May 17, 2013

KRAS mutation in patients with metastatic colorectal cancer does not preclude benefit from oxaliplatin-or irinotecan-based treatment.

KRAS mutation in patients with metastatic colorectal cancer does not preclude benefit from oxaliplatin-or irinotecan-based treatment.

Journal: Molecular and clinical oncology

Published: April 30, 2013

Practical utility of circulating tumour cells as biomarkers in cancer chemotherapy for advanced colorectal cancer.

Practical utility of circulating tumour cells as biomarkers in cancer chemotherapy for advanced colorectal cancer.

Journal: Anticancer research

Published: February 09, 2013

Clinical usefulness of KRAS, BRAF, and PIK3CA mutations as predictive markers of cetuximab efficacy in irinotecan- and oxaliplatin-refractory Japanese patients with metastatic colorectal cancer.

Clinical usefulness of KRAS, BRAF, and PIK3CA mutations as predictive markers of cetuximab efficacy in irinotecan- and oxaliplatin-refractory Japanese patients with metastatic colorectal cancer.

Journal: International journal of clinical oncology

Published: February 09, 2012

Showing 1-8 of 8

Last Updated: 09/26/2026